Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod

INTRODUCTION: Real-world clinical data suggest an attenuated short-term humoral response to SARS-CoV-2 vaccines in patients with multiple sclerosis (pwMS) receiving high efficacy (HE) disease modifying therapies (DMTs) such as Ocrelizumab (OCR) and Fingolimod (FNG). Long-term humoral response in pwM...

Descripción completa

Detalles Bibliográficos
Autores principales: Capuano, Rocco, Bisecco, Alvino, Conte, Miriana, Donnarumma, Giovanna, Altieri, Manuela, Grimaldi, Elena, Franci, Gianluigi, Chianese, Annalisa, Galdiero, Massimiliano, Coppola, Nicola, Tedeschi, Gioacchino, Gallo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895707/
https://www.ncbi.nlm.nih.gov/pubmed/35272145
http://dx.doi.org/10.1016/j.msard.2022.103724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895707/
https://www.ncbi.nlm.nih.gov/pubmed/35272145
http://dx.doi.org/10.1016/j.msard.2022.103724

Ejemplares similares